Unmet Needs in CML

Explore unmet needs in adult patients with newly diagnosed Ph+ CML-CP and how SCEMBLIX can provide an additional 1L treatment option.

Uncovering a Groundbreaking Study Design

The innovative ASC4FIRST study design evaluated SCEMBLIX vs current standard-of-care* TKIs in adult patients with newly diagnosed Ph+ CML-CP.

*Imatinib, nilotinib, dasatinib, and bosutinib.

Investigating the Clinical Data Supporting SCEMBLIX

Learn about the SCEMBLIX efficacy and safety/tolerability profile in adult patients with newly diagnosed Ph+ CML-CP as evaluated in the ASC4FIRST study, including key findings on primary and secondary end points.

Investigating the Safety Data

Dive into the safety and tolerability profile findings from the ASC4FIRST study analyzing SCEMBLIX and current standard-of-care TKIs.